RT期刊文章SR电子T1背景病理学corticobasal变性(CBD)模仿的日本验证研究CBD (J-VAC研究)——(P6.070)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P6.070 VO 90 15补充A1 Takayoshi Shimohata A1郁子Aiba A首页1 Mari吉田茂雄A1 Yasuko Toyoshima A1 Murayama A1——Uchihara A1 Tetsuaki Arai A1一郎Yabe A1 Takafumi长谷川A1从轻处置长谷川A1武Ikeuchi A1 Masato长谷川A1隆小森A1 Koichi若林史江A1阿雅Tokumaru A1凯塔樱井A1吴克群中岛美嘉A1 J-VAC研究小组2018年UL //www.ez-admanager.com/content/90/15_Supplement/P6.070.abstract AB目的:确定背景患者病理的日本“corticobasal变性(CBD)模仿”。背景:最近的研究集中在疾病修饰治疗CBD的发展,目标主要是在τ功能障碍。CBD的准确诊断越来越重要,但一个主要限制之间的临床表型相似性CBD和CBD模仿其他病理造成的。设计/方法:患者对他们详细的临床病理的研究结果,在那些被诊断为临床CBD中央审查期间或corticobasal综合症(CBS)。评估项目包括发病年龄、年龄在死亡时间,最终的临床诊断和临床体征和症状表现和在整个临床过程。结果:我们发现30病理确诊患者11日本机构。发病年龄为67.3±9.9 (±SD)年。疾病持续时间为7.5±2.9年。病理分析表明,进行性核上的麻痹(PSP)是最常见的诊断(37%),其次是阿尔茨海默病(广告;20%),球状胶质tauopathies (GGT;7%),和其他疾病包括与路易体痴呆(下文),选择疾病,额颞叶大叶性变性(FTLD)计划书或付,朊病毒疾病和胶质母细胞瘤。结论:“CBD模仿”包括4重复tauopathies (PSP和GGT;43%),non-4重复tauopathies(广告,选择疾病; 23%) and other diseases (DLB, FTLD, prion disease and glioblastoma etc.). Because disease-modifying treatments for CBD may also be beneficial for 4 repeat tauopathies, exclusion of non-4 repeat tauopathies and other diseases are absolutely necessary.Disclosure: Dr. Shimohata has nothing to disclose. Dr. Aiba has nothing to disclose. Dr. Yoshida has nothing to disclose. Dr. Toyoshima has nothing to disclose. Dr. Murayama has nothing to disclose. Dr. Uchihara has nothing to disclose. Dr. Arai has nothing to disclose. Dr. Yabe has nothing to disclose. Dr. Hasegawa has nothing to disclose. Dr. Hasegawa has nothing to disclose. Dr. Ikeuchi has nothing to disclose. Dr. Hasegawa has nothing to disclose. Dr. Komori has nothing to disclose. Dr. Wakabayashi has nothing to disclose. Dr. Tokumaru has nothing to disclose. Dr. Sakurai has nothing to disclose. Dr. Nakashima has nothing to disclose.